FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005603971> ?p ?o ?g. }

• W2005603971 endingPage "122" @default.
• W2005603971 startingPage "111" @default.
• W2005603971 abstract "Transition-metal-based compounds constitute a discrete class of chemotherapeutics, widely used in the clinic as antitumor and antiviral agents. Examples of established antitumor metallodrugs, routinely used in the clinic, are cisplatin [cis-diamminedichloroplatinum(II)] and its analogues carboplatin and oxaliplatin. However, drug resistance and side effects have limited their clinical utility. These limitations have prompted a search for more effective and less toxic metal-based antitumor agents. Some of the efforts have been directed in the design of non-platinum, transition-metal-based antitumor agents and ruthenium complexes have attracted much interest as alternative drugs to cisplatin in cancer chemotherapy. Ruthenium complexes demonstrate similar ligand exchange kinetics to those of platinum(II) antitumor drugs already used in the clinic while displaying only low toxicity. This is in part due to the ability of ruthenium complexes to mimic the binding of iron to molecules of biological significance, exploiting the mechanisms that the body has evolved for transport of iron. In addition, the redox potential between the different accessible oxidation states occupied by ruthenium complexes enables the body to catalyze oxidation and reduction reactions, depending on physiological environment. The biochemical changes that accompany cancer alter physiological environment, enabling ruthenium complexes to be selectively activated in cancer tissues. Due to differing ligand geometry between their complexes, ruthenium compounds bind to DNA affecting its conformation differently than cisplatin and its analogues. In addition, non-nuclear targets, such as the mitochondrion and the cell surface, have also been implicated in the antineoplastic activity of some ruthenium complexes. Thus, ruthenium compounds offer the potential over antitumor platinum(II) complexes currently used in the clinic of reduced toxicity, a novel mechanism of action, the prospect of non-cross-resistance and a different spectrum of activity. In other words, some chemical properties make ruthenium compounds well suited for medicinal applications and as an alternative to platinum antitumor drugs in the treatment of cancer cells resistant to cisplatin. Although the pharmacological target for antitumor ruthenium compounds has not been unequivocally identified, there is a large body of evidence indicating that the cytotoxicity of many ruthenium complexes correlates with their ability to bind DNA although few exceptions have been reported. This review summarizes results demonstrating that several ruthenium compounds that exhibit antitumor effects different from cisplatin or its analogues bind DNA and modify it differently than cisplatin or its analogues." @default.
• W2005603971 created "2016-06-24" @default.
• W2005603971 creator A5001459184 @default.
• W2005603971 creator A5081885555 @default.
• W2005603971 date "2006-06-01" @default.
• W2005603971 modified "2023-10-16" @default.
• W2005603971 title "DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity" @default.
• W2005603971 cites W1242125470 @default.
• W2005603971 cites W1511491270 @default.
• W2005603971 cites W1586119447 @default.
• W2005603971 cites W1741860215 @default.
• W2005603971 cites W177251887 @default.
• W2005603971 cites W1964314803 @default.
• W2005603971 cites W1968330562 @default.
• W2005603971 cites W1970105936 @default.
• W2005603971 cites W1970824205 @default.
• W2005603971 cites W1975104632 @default.
• W2005603971 cites W1980411311 @default.
• W2005603971 cites W1981582595 @default.
• W2005603971 cites W1981983703 @default.
• W2005603971 cites W1987461824 @default.
• W2005603971 cites W2000510569 @default.
• W2005603971 cites W2005241587 @default.
• W2005603971 cites W2009344089 @default.
• W2005603971 cites W2012108057 @default.
• W2005603971 cites W2014588550 @default.
• W2005603971 cites W2014966556 @default.
• W2005603971 cites W2015754709 @default.
• W2005603971 cites W2016408785 @default.
• W2005603971 cites W2028338260 @default.
• W2005603971 cites W2039790918 @default.
• W2005603971 cites W2041770648 @default.
• W2005603971 cites W2042246520 @default.
• W2005603971 cites W2042521338 @default.
• W2005603971 cites W2043610941 @default.
• W2005603971 cites W2045343949 @default.
• W2005603971 cites W2048168597 @default.
• W2005603971 cites W2050428483 @default.
• W2005603971 cites W2052153483 @default.
• W2005603971 cites W2053409523 @default.
• W2005603971 cites W2054607739 @default.
• W2005603971 cites W2059837825 @default.
• W2005603971 cites W2061103770 @default.
• W2005603971 cites W2065402334 @default.
• W2005603971 cites W2068922188 @default.
• W2005603971 cites W2068991440 @default.
• W2005603971 cites W2069148508 @default.
• W2005603971 cites W2076579315 @default.
• W2005603971 cites W2077594563 @default.
• W2005603971 cites W2084361832 @default.
• W2005603971 cites W2092261416 @default.
• W2005603971 cites W2094012917 @default.
• W2005603971 cites W2094765988 @default.
• W2005603971 cites W2096847256 @default.
• W2005603971 cites W2103459003 @default.
• W2005603971 cites W2105591137 @default.
• W2005603971 cites W2105790555 @default.
• W2005603971 cites W2111570380 @default.
• W2005603971 cites W2116360054 @default.
• W2005603971 cites W2121649359 @default.
• W2005603971 cites W2122684723 @default.
• W2005603971 cites W2129213133 @default.
• W2005603971 cites W2132797346 @default.
• W2005603971 cites W2140895245 @default.
• W2005603971 cites W2149687304 @default.
• W2005603971 cites W2153616465 @default.
• W2005603971 cites W2154244708 @default.
• W2005603971 cites W2155154899 @default.
• W2005603971 cites W2159190092 @default.
• W2005603971 cites W2170756410 @default.
• W2005603971 cites W2177162343 @default.
• W2005603971 cites W2316889091 @default.
• W2005603971 cites W4211092410 @default.
• W2005603971 cites W78319162 @default.
• W2005603971 cites W98290483 @default.
• W2005603971 doi "https://doi.org/10.1016/j.drup.2006.05.002" @default.
• W2005603971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16790363" @default.
• W2005603971 hasPublicationYear "2006" @default.
• W2005603971 type Work @default.
• W2005603971 sameAs 2005603971 @default.
• W2005603971 citedByCount "348" @default.
• W2005603971 countsByYear W20056039712012 @default.
• W2005603971 countsByYear W20056039712013 @default.
• W2005603971 countsByYear W20056039712014 @default.
• W2005603971 countsByYear W20056039712015 @default.
• W2005603971 countsByYear W20056039712016 @default.
• W2005603971 countsByYear W20056039712017 @default.
• W2005603971 countsByYear W20056039712018 @default.
• W2005603971 countsByYear W20056039712019 @default.
• W2005603971 countsByYear W20056039712020 @default.
• W2005603971 countsByYear W20056039712021 @default.
• W2005603971 countsByYear W20056039712022 @default.
• W2005603971 countsByYear W20056039712023 @default.
• W2005603971 crossrefType "journal-article" @default.
• W2005603971 hasAuthorship W2005603971A5001459184 @default.
• W2005603971 hasAuthorship W2005603971A5081885555 @default.
• W2005603971 hasConcept C116569031 @default.
• W2005603971 hasConcept C121608353 @default.

• next